Cited by 2,409Glioma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Response criteria for phase II studies of supratentorial malignant glioma.

Macdonald, D R, Cascino, T L, Schold, S C, Cairncross, J G·1990·Journal of Clinical Oncology

DOI 10.1200/jco.1990.8.7.1277

Open this paper in CoChat — free account

Abstract

We suggest "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four response categories are proposed: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response in this scheme is based on major changes in tumor size on the enhanced computed tomographic (CT) or magnetic resonance imaging (MRI) scan. Scan changes are interpreted in light of steroid use and neurologic findings. We advocate careful patient selection, emphasize pitfalls in the assessment of response, and suggest guidelines to minimize misinterpretations of response.

Integrity signals

Registry

Crossref · 10.1200/jco.1990.8.7.1277

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 345
Self-citation
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors
Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J., & Wilson, C. B. (1977) · Journal of neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone, A., Longo, D. L., Vt, D., Ihde, D. C., Duffey, P. L., Jaffe, E. S., Solomon, D., HUBBARD, S. M., & Young, R. C. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1832 · Cited by 178
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
Warr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas
Chamberlain, M. C., Murovic, J. A., & Levin, V. A. (1988) · Neurology · doi:10.1212/wnl.38.9.1371 · Cited by 149
Steroid‐induced CT changes in patients with recurrent malignant glioma
Cairncross, J. G., Macdonald, D. R., Pexman, J. H. W., & Ives, F. J. (1988) · Neurology · doi:10.1212/wnl.38.5.724 · Cited by 100
Self-citation
Computerized tomography in the prognosis of malignant cerebral gliomas
Murovic, J. A., Turowski, K., Wilson, C. B., Hoshino, T., & Levin, V. A. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.65.6.0799 · Cited by 42
Criteria and definitions for response and relapse in children with brain tumors
Zeltzer, P. M., Friedman, H. S., Norris, D. G., & Ragab, A. H. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7+ · Cited by 35
Post-Surgical Contrast Enhancement Mimicking Residual Brain Tumour
Cairncross, J. G., Pexman, J. H. W., & Rathbone, M. P. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046643 · Cited by 33
Self-citation
The accuracy of volumetric measurement of high-grade gliomas
Chisholm, R. A., Stenning, S. P., & Hawkins, T. D. (1989) · Clinical Radiology · doi:10.1016/s0009-9260(89)80007-8 · Cited by 32

Flagged first, then by citations

Show all 11 references

Sorted by citations

Items 101–200 of 1,001

Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma
Soussain, C., Suzan, F., Hoang‐Xuan, K., Cassoux, N., Lévy, V., Azar, N., Bélanger, C., Achour, E., Ribrag, V., Gerber, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.742 · Cited by 320
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Weller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J. P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2737 · Cited by 339
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide
Minniti, G. C., Amelio, D., Amichetti, M., Salvati, M., Muni, R., Bozzao, A., Lanzetta, G., Scarpino, S., Arcella, A., & Enrici, R. M. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.08.020 · Cited by 319
Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
Pope, W. B., Kim, G. H. J., Huo, J., Alger, J. R., Brown, M. S., Gjertson, D., Sai, V., Young, J. R., Tekchandani, L., Cloughesy, T. F., et al. (2009) · Radiology · doi:10.1148/radiol.2521081534 · Cited by 318
A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses
Markert, J. M., Razdan, S. N., Kuo, H., Cantor, A. B., Knoll, A. E., Karrasch, M., Nabors, B., Markiewicz, M. A., Agee, B. S., Coleman, J. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.22 · Cited by 317
Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
Quinn, J. A., Jiang, X. “., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 314
Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
Beier, D., Schulz, J. B., & Beier, C. P. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-128 · Cited by 308
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T., & Dietrich, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.204 · Cited by 317
Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study
Stummer, W., Tonn, J., Mehdorn, H. M., Nestler, U., Franz, K., Goetz, C., Bink, A., & Pichlmeier, U. (2010) · Journal of neurosurgery · doi:10.3171/2010.3.jns097 · Cited by 313
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
IWAMOTO, F. M., Abrey, L. E., Beal, K. P., Gutin, P. H., Rosenblum, M. K., Reuter, V. E., DeAngelis, L. M., & Lassman, A. B. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc0184 · Cited by 306
Measures of Response: RECIST, WHO, and New Alternatives
Jaffe, C. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5599 · Cited by 302
Diffuse intrinsic pontine glioma: poised for progress
Warren, K. E. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00205 · Cited by 301
High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma
Illerhaus, G., Marks, R., Ihorst, G., Guttenberger, R., Ostertag, C. B., Derigs, G., Frickhofen, N., Feuerhake, F., Volk, B., & Finke, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2117 · Cited by 298
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K., Wen, P. Y., et al. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop015 · Cited by 306
Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
van den Bent, M. J., TAPHOORN, M. J. B., Brandes, A. A., Menten, J. J., Stupp, R., Frénay, M., Chinot, O. L., Kros, J. M., van der Rijt, C. C. D., Vecht, C. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.015 · Cited by 295
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Kaley, T. J., Wen, P. Y., Schiff, D., Ligon, K. L., Haidar, S., Karimi, S., Lassman, A. B., Nolan, C. P., DeAngelis, L. M., Gavrilovic, I. T., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou148 · Cited by 292
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma
Qi, S., Yu, L., Gui, S., YanQing, D., HuiXia, H., Xue-lin, Z., Lanxiao, W., & Fei, Y. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02134.x · Cited by 290
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma
Hamstra, D. A., Chenevert, T. L., Moffat, B. A., Johnson, T. D., Meyer, C. R., Mukherji, S. K., Quint, D. J., Gebarski, S. S., Fan, X., Tsien, C. I., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508347102 · Cited by 285
An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., Herndon, J. E., Lally-Goss, D., McGehee-Norman, S., Paolino, A., Reardon, D. A., Friedman, A. H., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0124 · Cited by 285
ERGO: A pilot study of ketogenic diet in recurrent glioblastoma
Rieger, J., Bähr, O., Maurer, G. D., Hattingen, E., Franz, K., Brucker, D. P., Walenta, S., Kämmerer, U., Coy, J. F., Weller, M., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2382 · Cited by 284
Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival
Hamstra, D. A., Galbán, C. J., Meyer, C. R., Johnson, T. D., Sundgren, P. C., Tsien, C. I., Lawrence, T. S., Junck, L., Ross, D. J., Rehemtulla, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2363 · Cited by 282
Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology
Brandes, A. A., Tosoni, A., Spagnolli, F., Frezza, G., Leonardi, M., Calbucci, F., & Franceschi, E. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-008 · Cited by 280
Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach
Rockne, R. C., Rockhill, J. K., Mrugała, M. M., Spence, A. M., Kalet, I. J., Hendrickson, K. R. G., Lai, A., Cloughesy, T. F., Alvord, E. C., & Swanson, K. R. (2010) · Physics in Medicine and Biology · doi:10.1088/0031-9155/55/12/001 · Cited by 278
Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity
Ellingson, B. M., Malkin, M. G., Rand, S. D., Connelly, J., Quinsey, C. S., LaViolette, P. S., Bedekar, D. P., & Schmainda, K. M. (2010) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22068 · Cited by 278
A Phase I Trial of Intratumoral Administration of Reovirus in Patients With Histologically Confirmed Recurrent Malignant Gliomas
Forsyth, P. A., Roldán, G. B., George, D. H., Wallace, C. J., Palmer, C. A., Morris, D. G., Cairncross, G. J., Matthews, M. V., Markert, J. M., Gillespie, G. Y., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300403 · Cited by 275
Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours
O'Reilly, S. M., Newlands, E. S., Brampton, M., Glaser, M. G., Rice-Edwards, J. M., Illingworth, R. D., Richards, P. G., Christopher Kennard, C., Colquhoun, I. R., Lewis, P. D., et al. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80198-4 · Cited by 275
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review
Kaley, T. J., Barani, I. J., Chamberlain, M. C., McDermott, M. W., Panageas, K., Raizer, J. J., Rogers, L. R., Schiff, D., Vogelbaum, M. A., Weber, D., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not330 · Cited by 274
Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival
Spence, A. M., Muzi, M., Swanson, K. R., O’Sullivan, F., Rockhill, J. K., Rajendran, J. G., Adamsen, T. C. H., Link, J. M., Swanson, P. E., Yagle, K. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4995 · Cited by 282
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
Zuniga, R. M., Torcuator, R., Jain, R., Anderson, J. E., Doyle, T. J., Ellika, S., Schultz, L., & Mikkelsen, T. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9718-y · Cited by 273
Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities
Itakura, H., Achrol, A. S., Mitchell, L. A., Loya, J. J., Liu, T. T., Westbroek, E. M., Feroze, A. H., Rodriguez, S., Echegaray, S., Azad, T. D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7582 · Cited by 270
Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme
Vleeschouwer, S. D., Fieuws, S., Rutkowski, S., Calenbergh, F. V., Loon, J. V., Goffin, J., Sciot, R., Wilms, G., Demaerel, P., Warmuth‐Metz, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4875 · Cited by 272
Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study
Tedeschi, G., Lundbom, N. M. I., Raman, R., Bonavita, S., Duyn, J. H., Alger, J. R., & Chiro, G. D. (1997) · Journal of neurosurgery · doi:10.3171/jns.1997.87.4.0516 · Cited by 269
Low-Grade Gliomas
Forst, D. A., Nahed, B. V., Loeffler, J. S., & Batchelor, T. T. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0345 · Cited by 267
Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data
Lehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones‐Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.025 · Cited by 273
Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
Yamanaka, R., Abe, T., Yajima, N., Tsuchiya, N., Homma, J., Kobayashi, T., Narita, M., Takahashi, M., & Tanaka, R. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601268 · Cited by 262
Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan
Sathornsumetee, S., Cao, Y., Marcello, J. E., Herndon, J. E., McLendon, R. E., Desjardins, A., Friedman, H. S., Dewhirst, M. W., Vredenburgh, J. J., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3652 · Cited by 262
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response
Pace, A., Vidiri, A., Galiè, E., Carosi, M., Telera, S. M., Cianciulli, A. M., Canalini, P., Giannarelli, D., Jandolo, B., & Carapella, C. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg502 · Cited by 261
Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma
Wick, A., Felsberg, J., Steinbach, J. P., Herrlinger, U., Platten, M., Blaschke, B., Meyermann, R., Reifenberger, G., Weller, M., & Wick, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7722 · Cited by 260
Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice
Chukwueke, U. N., & Wen, P. Y. (2019) · CNS Oncology · doi:10.2217/cns-2018-0007 · Cited by 262
Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management
Wang, Y., & Jiang, T. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.12.024 · Cited by 264
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
Geletneky, K., Hajda, J., Angelova, A. L., Leuchs, B., Capper, D., Bartsch, A. J., Neumann, J., Schöning, T., Hüsing, J., Beelte, B., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.016 · Cited by 263
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Reifenberger, G., Hentschel, B., Felsberg, J., Schackert, G., Simon, M., Schnell, O., Westphal, M., Wick, W., Pietsch, T., Loeffler, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27385 · Cited by 256
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial
Suchorska, B., Weller, M., Tabatabai, G., Senft, C., Hau, P., Sabel, M., Herrlinger, U., Ketter, R., Schlegel, U. S., Marosi, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov326 · Cited by 268
Current and future developments in the use of temozolomide for the treatment of brain tumours
Stupp, R., Gander, M., Leyvraz, S., & Newlands, E. S. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00489-2 · Cited by 254
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
Lassman, A. B., Rossi, M. R., Razier, J. R., Abrey, L. E., Lieberman, F. S., Grefe, C. N., Lamborn, K. R., Pao, W. J., Shih, A. H., Kuhn, J. G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0421 · Cited by 252
GBM Volumetry using the 3D Slicer Medical Image Computing Platform
Egger, J., Kapur, T., Fedorov, A., Pieper, S., Miller, J. V., Veeraraghavan, H., Freisleben, B., Golby, A. J., Nimsky, C., & Kikinis, R. (2013) · Scientific Reports · doi:10.1038/srep01364 · Cited by 252
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J., D'Hondt, L. A., Strauven, T., Chaskis, C., Veld, P. I. '., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 260
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria
Nayak, L., DeAngelis, L. M., Brandes, A. A., Peereboom, D. M., Galanis, E., Lin, N., Soffietti, R., Macdonald, D. R., Chamberlain, M. C., Perry, J., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox029 · Cited by 248
Self-citation
Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal Abnormalities
Buckner, J. C., Gesme, D. H., O'Fallon, J. R., Hammack, J. E., Stafford, S., Brown, P. D., Hawkins, R. B., Scheithauer, B. W., Erickson, B. J., Levitt, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.023 · Cited by 248
Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape
Ellingson, B. M., Chung, C. D., Pope, W. B., Boxerman, J. L., & Kaufmann, T. J. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2375-2 · Cited by 247
Conventional MRI evaluation of gliomas
Upadhyay, N., & Waldman, A. D. (2011) · British Journal of Radiology · doi:10.1259/bjr/65711810 · Cited by 246
Antiangiogenic therapies for high-grade glioma
Norden, A. D., Drappatz, J., & Wen, P. Y. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.159 · Cited by 253
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
Emblem, K. E., Mouridsen, K., Bjørnerud, A., Farrar, C. T., Jennings, D. L., Borra, R., Wen, P. Y., Ivy, P. S., Batchelor, T. T., Rosen, B. R., et al. (2013) · Nature Medicine · doi:10.1038/nm.3289 · Cited by 251
Brainstem gliomas in adults: prognostic factors and classification
Guillamo, J. (2001) · Brain · doi:10.1093/brain/124.12.2528 · Cited by 244
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
Nabors, B., Fink, K., Mikkelsen, T., Grujičić, D., Tarnawski, R., Nam, D. H., Mazurkiewicz, M., Salacz, M. E., Ashby, L. S., Zagonel, V., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou356 · Cited by 242
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
Narayana, A., Kelly, P., Golfinos, J. G., Parker, E. C., Johnson, G., Knopp, E. A., Zagzag, D., Fischer, I., Raza, S., Medabalmi, P., et al. (2008) · Journal of neurosurgery · doi:10.3171/2008.4.17492 · Cited by 242
Emerging Applications of Artificial Intelligence in Neuro-Oncology
Rudie, J. D., Rauschecker, A. M., Bryan, R. N., Davatzikos, C. A., & Mohan, S. (2019) · Radiology · doi:10.1148/radiol.2018181928 · Cited by 247
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors
Dunbar, E. M., Coats, B. S., Shroads, A. L., Langaee, T., Lew, A., Forder, J. R., Shuster, J. J., Wagner, D. A., & Stacpoole, P. W. (2014) · Investigational New Drugs · doi:10.1007/s10637-013-0047-4 · Cited by 241
Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial
Bloch, O. G., Crane, C. A., Fuks, Y. S., Kaur, R., Aghi, M. K., Berger, M. S., Butowski, N. A., Chang, S. M., Clarke, J. L., McDermott, M. W., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not203 · Cited by 241
Results of Whole-Brain Radiation As Salvage of Methotrexate Failure for Immunocompetent Patients With Primary CNS Lymphoma
Nguyen, P. L., Chakravarti, A., Finkelstein, D. M., Hochberg, F. H., Batchelor, T. T., & Loeffler, J. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.161 · Cited by 238
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
van den Bent, M. J., Vogelbaum, M. A., Wen, P. Y., Macdonald, D. R., & Chang, S. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4998 · Cited by 240
Self-citation
Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience
Angelov, L., Doolittle, N. D., Kraemer, D. F., Siegal, T., Barnett, G. H., Peereboom, D. M., Stevens, G. H. J., McGregor, J., Jahnke, K., Lacy, C. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3789 · Cited by 236
First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1380 · Cited by 239
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Wick, W., Meisner, C., Hentschel, B., Platten, M., Schilling, A., Wiestler, B., Sabel, M., Koeppen, S., Ketter, R., Weiler, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a95680 · Cited by 235
Multifaceted end points in brain tumor clinical trials: Cognitive deterioration precedes MRI progression
Meyers, C. A., & Hess, K. R. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.89 · Cited by 234
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Fangusaro, J., Witt, O., Driever, P. H., Bag, A. K., de Blank, P. M. K., Kadom, N., Kilburn, L. B., Lober, R. M., Robison, N. J., Fisher, M. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30064-4 · Cited by 234
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Herndon, J. E., Marcello, J. E., Norfleet, J. A., McLendon, R. E., Sampson, J. H., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9950-0 · Cited by 235
Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma
Bouffet, É., Jakacki, R. I., Goldman, S., Hargrave, D. R., Hawkins, C. E., Shroff, M. M., Hukin, J., Bartels, U. K., Foreman, N. K., Kellie, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.5843 · Cited by 231
Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas
Vogelbaum, M. A., Jost, S. C., Aghi, M. K., Heimberger, A. B., Sampson, J. H., Wen, P. Y., Macdonald, D., van den Bent, M. J., & Chang, S. M. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318223f5a7 · Cited by 231
Self-citation
A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
Rodon, J. A., Tawbi, H. A.-H., Thomas, A., Stoller, R. G., Turtschi, C. P., Baselga, J. M., Sarantopoulos, J., Mahalingam, D., Shou, Y., Moles, M. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1710 · Cited by 230
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J. E., Herndon, J. E., Mathe, A., Hamilton, M., Rich, J. N., Norfleet, J. A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq099 · Cited by 230
The Diagnosis and Treatment of Pseudoprogression, Radiation Necrosis and Brain Tumor Recurrence
Parvez, K., Parvez, A., & Zadeh, G. M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150711832 · Cited by 229
Primary central nervous system post‐transplantation lymphoproliferative disorder
Cavaliere, R., Petroni, G. R., Lopes, M. B. S., & Schiff, D. (2010) · Cancer · doi:10.1002/cncr.24834 · Cited by 229
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
Hasselbalch, B., Lassen, U., Hansen, S., Holmberg, M., Mau‐Sørensen, M., Kosteljanetz, M., Broholm, H., Stockhausen, M., & Poulsen, H. S. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop063 · Cited by 229
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients
Minniti, G. C., Sanctis, V. D., Muni, R., Filippone, F., Bozzao, A., Valeriani, M., Osti, M. F., Paula, U. D., Lanzetta, G., Tombolini, V., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9538-0 · Cited by 227
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
de Groot, J., Lamborn, K. R., Chang, S. M., Gilbert, M. R., Cloughesy, T. F., Aldape, K., Yao, J., Jackson, E. F., Lieberman, F. S., Robins, H. I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1636 · Cited by 234
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma
Brandes, A. A., Franceschi, E., Tosoni, A., Benevento, F., Scopece, L., Mazzocchi, V., Bacci, A., Agati, R., Calbucci, F., & Ermani, M. (2009) · Cancer · doi:10.1002/cncr.24406 · Cited by 226
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
Brandes, A. A., Tosoni, A., Cavallo, G., Bertorelle, R., Gioia, V., Franceschi, E., Biscuola, M., Blatt, V., Crinò, L., & Ermani, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603376 · Cited by 226
Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
Raymond, É., Brandes, A. A., Dittrich, C., Fumoleau, P., Coudert, B. P., Clément, P. M., Frénay, M., Rampling, R., Stupp, R., Kros, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9235 · Cited by 225
Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)
Kirson, E. D., Schneiderman, R. S., Dbalý, V., Tovaryš, F., Vymazal, J., Itzhaki, A., Mordechovich, D., Gurvich, Z., Shmueli, E., Goldsher, D., et al. (2009) · BMC Medical Physics · doi:10.1186/1756-6649-9-1 · Cited by 224
Adenoma-carcinoma sequence or “de novo” Carcinogenesis?. A study of adenomatous remnants in a population-based series of large bowel cancers
Bedenne, L., Faivre, J., Boutron‐Ruault, M., Piard, F., Cauvin, J.-M., & Hillon, P. (1992) · Cancer · doi:10.1002/1097-0142(19920215)69:4 · Cited by 181
Temozolomide for high grade glioma
Hart, M. G., Garside, R., Rogers, G., Stein, K., & Grant, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007415.pub2 · Cited by 223
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
IWAMOTO, F. M., Lamborn, K. R., Robins, H. I., Mehta, M. P., Chang, S., Butowski, N. A., DeAngelis, L. M., Abrey, L. E., Zhang, W., Prados, M. D., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq025 · Cited by 221
Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging
Fink, J. R., Muzi, M., Peck, M., & Krohn, K. A. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131516 · Cited by 230
The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology
Cagney, D. N., Sul, J., Huang, R. Y., Ligon, K. L., Wen, P. Y., & Alexander, B. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox242 · Cited by 234
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Tsien, C. I., Pugh, S. L., Dicker, A. P., Raizer, J. J., Matuszak, M. M., Lallana, E. C., Huang, J., Algan, Ö., Deb, N., Portelance, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00164 · Cited by 221
Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrocytomas
Andrews, D. W., Resnicoff, M., Flanders, A. E., Kenyon, L. C., Curtis, M. T., Merli, G., Baserga, R., Iliakis, G. E., & Aiken, R. D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2189 · Cited by 219
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group
Huang, R. Y., Bi, W. L., Weller, M., Kaley, T. J., Blakeley, J. O., Dunn, I. F., Galanis, E., Preusser, M., McDermott, M. W., Rogers, L., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy137 · Cited by 218
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
Bower, M., Newlands, E. S., Bleehen, N. M., Brada, M., Beǵent, R. H. J., Calvert, H., Colquhoun, I. R., Lewis, P., & Brampton, M. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050691 · Cited by 218
Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival
Hu, L., Eschbacher, J. M., Heiserman, J. E., Dueck, A. C., Shapiro, W. R., Liu, S., Karis, J. P., Smith, K. A., Coons, S. W., Nakaji, P., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos112 · Cited by 216
Inhibition of TGF- β 2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies
Hau, P., Jachimczak, P., Schlingensiepen, R., Schulmeyer, F. J., Jauch, T., Steinbrecher, A., Brawanski, A. T., Proescholdt, M. A., Schlaier, J. R., Buchroithner, J., et al. (2007) · Oligonucleotides · doi:10.1089/oli.2006.0053 · Cited by 215
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
Friday, B. B., Anderson, S. K., Buckner, J. F., Yu, C., Giannini, C., Geoffroy, F., Schwerkoske, J. F., Mazurczak, M. A., Gross, H. M., Pajon, E. R., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor198 · Cited by 214
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
Westphal, M., Heese, O., Steinbach, J. P., Schnell, O., Schackert, G., Mehdorn, H. M., Schulz, D., Simon, M., Schlegel, U. S., Senft, C., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.019 · Cited by 218
Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas
Zikou, A. K., Sioka, C., Alexiou, G. Α., FOTOPOULOS, A. D., Voulgaris, S., & Argyropoulou, M. I. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/6828396 · Cited by 212
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Franceschi, E., Cavallo, G., Lonardi, S., Magrini, E., Tosoni, A., Grosso, D., Scopece, L., Blatt, V., Urbini, B., Pession, A., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603669 · Cited by 211
Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma
Tsien, C. I., Galbán, C. J., Chenevert, T. L., Johnson, T. D., Hamstra, D. A., Sundgren, P. C., Junck, L., Meyer, C. R., Rehemtulla, A., Lawrence, T. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3971 · Cited by 211
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1
Carpentier, A. C., Laigle–Donadey, F., Zohar, S., Capelle, L., Béhin, A., Tibi, A., Martin-Duverneuil, N., Sanson, M., Lacomblez, L., Taillibert, S., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000475 · Cited by 212
Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy
Kreth, F.-W., Thon, N., Simon, M., Westphal, M., Schackert, G., Nikkhah, G., Hentschel, B., Reifenberger, G., Pietsch, T., Weller, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt388 · Cited by 223
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods
Mountz, J. M., Ahmed, R., Oborski, M. J., Lieberman, F. S., & Hwang, M. (2014) · Cancer Management and Research · doi:10.2147/cmar.s54726 · Cited by 214
Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
Pérez‐Larraya, J. G., Ducray, F., Chinot, O. L., Catry‐Thomas, I., Taillandier, L., Guillamo, J., Campello, C., Monjour, A., Cartalat‐Carel, S., Barrié, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8086 · Cited by 210

Authors: Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G.
Affiliations: Western University (CA)
ORCID: Cairncross, J G
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1990-07
Volume: 8
Issue: 7
Pages: 1277-1280
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1990.8.7.1277
OpenAlex: W1959628099
Cited by: 2,409
References: 11
Citations by year: 2026: 31 · 2025: 21 · 2024: 36 · 2023: 52 · 2022: 53 · 2021: 59 · 2020: 68 · 2019: 75 · 2018: 97 · 2017: 111 · 2016: 125 · 2015: 122 · 2014: 161 · 2013: 186 · 2012: 145
FWCI: 3.90
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: high-grade glioma, supratentorial glioma, response criteria, tumor size measurement, complete response, partial response, stable disease, progressive disease, steroid use, neurologic findings, patient selection, magnetic resonance imaging, computed tomography
MeSH terms: Diagnostic Errors, Drug Evaluation, Glioma, Humans, Magnetic Resonance Imaging, Medical Oncology, Tomography, X-Ray Computed, Supratentorial Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Response criteria for phase II studies of supratentorial malignant glioma.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks